Status:
UNKNOWN
Prognostic Impact of Delta-haemolysin Production Deficiency in Staphylococcus Aureus on the Prognosis of Infected Implant Treated by DAIR
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Bone and Joint Infection
Staphylococcus Aureus
Eligibility:
All Genders
18-99 years
Brief Summary
The aim of this study is to determine if delta-haemolysin production deficiency of Staphylococcus aureus is a marker in favour of chronic infections on implants
Eligibility Criteria
Inclusion
- patients having implant infection due to S. aureus treated by DAIR
Exclusion
- none
Key Trial Info
Start Date :
January 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03796104
Start Date
January 1 2018
End Date
December 31 2023
Last Update
April 13 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospices Civils de Lyon
Lyon, France, 69004